Fierce Biotech

Dimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M deal

Dimerix has bought an acute kidney injury (AKI) drug from Mission Therapeutics, paying (PDF) $5 million upfront and ...